
Brian A. Whiteman
Examiner (ID: 15660, Phone: (571)272-0764 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1674, 1636, 1633, 1635 |
| Total Applications | 1778 |
| Issued Applications | 936 |
| Pending Applications | 245 |
| Abandoned Applications | 622 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16728140
[patent_doc_number] => 20210095287
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-01
[patent_title] => MICRORNA-BASED LOGIC GATES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/032259
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032259
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/032259 | MicroRNA-based logic gates and uses thereof | Sep 24, 2020 | Issued |
Array
(
[id] => 18733560
[patent_doc_number] => 11802283
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-31
[patent_title] => Oligonucleotide analogues targeting human LMNA
[patent_app_type] => utility
[patent_app_number] => 17/024100
[patent_app_country] => US
[patent_app_date] => 2020-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 19489
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/024100 | Oligonucleotide analogues targeting human LMNA | Sep 16, 2020 | Issued |
Array
(
[id] => 16808277
[patent_doc_number] => 20210130830
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-06
[patent_title] => APTAMERS SPECIFIC FOR TLR-4 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/022984
[patent_app_country] => US
[patent_app_date] => 2020-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21932
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022984
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/022984 | Aptamers specific for TLR-4 and uses thereof | Sep 15, 2020 | Issued |
Array
(
[id] => 17037103
[patent_doc_number] => 20210254061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
[patent_app_type] => utility
[patent_app_number] => 17/019154
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67737
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019154
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/019154 | Systems and methods for the treatment of hemoglobinopathies | Sep 10, 2020 | Issued |
Array
(
[id] => 16709502
[patent_doc_number] => 20210076649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => COMPOSITIONS AND METHODS FOR CHARACTERIZING A MICROBIOME
[patent_app_type] => utility
[patent_app_number] => 17/019183
[patent_app_country] => US
[patent_app_date] => 2020-09-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23518
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019183
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/019183 | Compositions and methods for characterizing a microbiome | Sep 10, 2020 | Issued |
Array
(
[id] => 18844997
[patent_doc_number] => 20230407401
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => DNA DAMAGE DEPENDENT MICRORNA SIGNATURE FOR CANCERS, METHODS AND USES RELATED THERETO
[patent_app_type] => utility
[patent_app_number] => 17/998888
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21813
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998888
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998888 | DNA DAMAGE DEPENDENT MICRORNA SIGNATURE FOR CANCERS, METHODS AND USES RELATED THERETO | Sep 3, 2020 | Pending |
Array
(
[id] => 18642414
[patent_doc_number] => 11766467
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-26
[patent_title] => Methods of treating wounds using cathepsin K inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/006003
[patent_app_country] => US
[patent_app_date] => 2020-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 14
[patent_no_of_words] => 13760
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006003
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/006003 | Methods of treating wounds using cathepsin K inhibitors | Aug 27, 2020 | Issued |
Array
(
[id] => 17867411
[patent_doc_number] => 20220290147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => SYSTEM FOR REGULATING GENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/638619
[patent_app_country] => US
[patent_app_date] => 2020-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12463
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638619
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/638619 | SYSTEM FOR REGULATING GENE EXPRESSION | Aug 27, 2020 | Pending |
Array
(
[id] => 16569192
[patent_doc_number] => 20210008198
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE
[patent_app_type] => utility
[patent_app_number] => 16/999948
[patent_app_country] => US
[patent_app_date] => 2020-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999948
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/999948 | Immunotherapeutic constructs and methods of their use | Aug 20, 2020 | Issued |
Array
(
[id] => 18413385
[patent_doc_number] => 11667920
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Methods for treating brain injury
[patent_app_type] => utility
[patent_app_number] => 16/996616
[patent_app_country] => US
[patent_app_date] => 2020-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 53
[patent_no_of_words] => 21465
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996616
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/996616 | Methods for treating brain injury | Aug 17, 2020 | Issued |
Array
(
[id] => 17800378
[patent_doc_number] => 11414663
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-16
[patent_title] => Micro-RNA profiling, compositions, and methods of treating diseases
[patent_app_type] => utility
[patent_app_number] => 16/995586
[patent_app_country] => US
[patent_app_date] => 2020-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 11
[patent_no_of_words] => 11792
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16995586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/995586 | Micro-RNA profiling, compositions, and methods of treating diseases | Aug 16, 2020 | Issued |
Array
(
[id] => 19051219
[patent_doc_number] => 20240093188
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => RNAi AGENT TARGETING MYD88 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/927427
[patent_app_country] => US
[patent_app_date] => 2020-08-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927427
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/927427 | RNAi AGENT TARGETING MYD88 AND USE THEREOF | Aug 12, 2020 | Issued |
Array
(
[id] => 16688701
[patent_doc_number] => 20210071177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
[patent_app_type] => utility
[patent_app_number] => 16/988391
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988391
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/988391 | Modified oligonucleotides targeting SNPs | Aug 6, 2020 | Issued |
Array
(
[id] => 16868601
[patent_doc_number] => 20210162068
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA
[patent_app_type] => utility
[patent_app_number] => 16/941028
[patent_app_country] => US
[patent_app_date] => 2020-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27820
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16941028
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/941028 | Treatment of primary ciliary dyskinesia with synthetic messenger RNA | Jul 27, 2020 | Issued |
Array
(
[id] => 20826544
[patent_doc_number] => 12680101
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-07-14
[patent_title] => RNA molecule, chimeric NA molecule, double-stranded RNA molecule, and double-stranded chimeric NA molecule
[patent_app_type] => utility
[patent_app_number] => 17/626867
[patent_app_country] => US
[patent_app_date] => 2020-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 9147
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626867
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/626867 | RNA molecule, chimeric NA molecule, double-stranded RNA molecule, and double-stranded chimeric NA molecule | Jul 15, 2020 | Issued |
Array
(
[id] => 16569220
[patent_doc_number] => 20210008226
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => SYSTEMIC DELIVERY OF MYOSTATIN SHORT INTERFERING NUCLEIC ACIDS (SINA) CONJUGATED TO A LIPOPHILIC MOIETY
[patent_app_type] => utility
[patent_app_number] => 16/910237
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910237
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/910237 | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety | Jun 23, 2020 | Issued |
Array
(
[id] => 17815631
[patent_doc_number] => 11421230
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => AAV-based treatment of cholesterol-related disorders
[patent_app_type] => utility
[patent_app_number] => 16/908798
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 47
[patent_no_of_words] => 21917
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908798
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/908798 | AAV-based treatment of cholesterol-related disorders | Jun 22, 2020 | Issued |
Array
(
[id] => 17875774
[patent_doc_number] => 11447777
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
[patent_app_type] => utility
[patent_app_number] => 16/908313
[patent_app_country] => US
[patent_app_date] => 2020-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 31
[patent_no_of_words] => 51263
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16908313
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/908313 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | Jun 21, 2020 | Issued |
Array
(
[id] => 17815634
[patent_doc_number] => 11421233
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Methods relating to circulating tumor cell clusters and the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 16/902316
[patent_app_country] => US
[patent_app_date] => 2020-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 49
[patent_no_of_words] => 37798
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16902316
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/902316 | Methods relating to circulating tumor cell clusters and the treatment of cancer | Jun 15, 2020 | Issued |
Array
(
[id] => 16329909
[patent_doc_number] => 20200300875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => ApoCIII and the Treatment and Diagnosis of Diabetes
[patent_app_type] => utility
[patent_app_number] => 16/898849
[patent_app_country] => US
[patent_app_date] => 2020-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898849
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898849 | ApoCIII and the Treatment and Diagnosis of Diabetes | Jun 10, 2020 | Abandoned |